Search

Objectives: To assess the efficacy and safety of preoperative neoadjuvant everolimus in renal angiomyolipomas (AML) patients with or without Tuberous Sclerosis Complex (TSC). Materials and Methods: This multi‐institutional retrospective study enrolled renal AML patients who underwent partial nephrectomy (PN) or total nephrectomy after receiving at least 1 month of pre‐operative everolimus. Imaging evaluations were collected before and after treatment, along with demographic, surgical, and follow‐up information. The primary outcome was tumor volume reduction of ≥25%, with additional outcomes including recurrence, perioperative outcomes, renal function, and safety. Results: From January 2015 to July 2022, 68 renal AML patients were studied—41 with TSC and 27 without. During everolimus treatment, 61.0% (25/41) of TSC patients and 44.4% (12/27) of non‐TSC patients achieved tumor reduction of ≥25%. Additionally, 41.5% (17/41) of TSC patients and 18.5% (5/27) of non‐TSC patients achieved a ≥ 50% reduction. Three TSC patients and 1 non‐TSC patient discontinued treatment due to side‐effects. Most patients (92.7% TSC, 85.2% non‐TSC) underwent PN. After everolimus treatment, the necessary total nephrectomy decreased to 41.2% (7/17) from baseline. Postoperatively, 1 grade 3 and 3 grade 2 complications occurred, with no grade 4 or 5 complications. After a median follow‐up of 24 months, only 1 TSC patient recurred with a diameter >3 cm. Retrospective nature is the major limitation of this study. Conclusion: Everolimus was effective and well‐tolerated in neoadjuvant treatment for renal AML, especially in TSC patients. This neoadjuvant combination strategy of everolimus and PN could effectively controls recurrence and preserves renal function. [ABSTRACT FROM AUTHOR]

Introduction: This retrospective study aimed to evaluate the prognostic value of [ 18 F]FDG parameters in patients with visceral and bone metastatic hormone-sensitive prostate cancer (mHSPC)., Patients and Methods: This analysis included the mHSPC patients who underwent [ 18 F]FDG PET/CT at the initial diagnosis. Baseline characteristics were analyzed, and the uptake of [ 18 F]FDG was quantified using SUV max . Kaplan-Meier and Cox proportional hazard regression analysis were employed to evaluate the correlation between SUV max and patient survival., Results: Among the 267 patients enrolled, 90 (33.7%) presented with visceral metastases and 177 (66.3%) had bone metastases. The median follow-up for the visceral metastasis group was 35.5 months (IQR 26-53.8 months). The median overall survival for patients with lung, liver, or both metastases were 30, 21 and 17 months, respectively. Patients exhibiting higher [ 18 F]FDG uptake in metastatic lesions experienced shorter overall survival (OS) in comparison to those with lower [ 18 F]FDG uptake, both in the visceral metastases group (17 vs. 31 months, p  = 0.002) and the bone metastases group (27.5 vs. 34.5 months, p  < 0.001). Cox regression analysis further revealed that increased [ 18 F]FDG uptake in metastatic lesions emerged as a significant risk factor in both OS and progression-free survival (PFS). In contrast, the variability in [ 18 F]FDG uptake in primary lesions did not provide a reliable indicator for predicting prognosis., Conclusions: In mHSPC patients, higher [ 18 F]FDG uptake in metastatic lesions indicates shorter survival and increased risk of disease progression. The [ 18 F]FDG SUV max in primary tumors did not show significant prognostic value. Our study underscores the unique prognostic potential of [ 18 F]FDG PET/CT in mHSPC patients, highlighting its importance in the management of both bone and visceral metastases.